Summary
Fifty-four evaluable patients with SCLC previously treated with chemotherapy received either N-methylformamide or spirogermanium. There was one partial response to N-methylformamide. The median survival times for patients treated with N-MF and spirogermanium were 11.7 and 12.6 weeks respectively. Five patients treated with N-MF experienced severe toxicity while four patients treated with spirogermanium experienced severe and life-threatening toxicity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Tanaka M, Levy J, Terada M, Breslow R, Rifkind RA, Marks PA: Induction of erythroid differentiation in murine virus infected erytholeukemia cells by highly polar compounds. Proc Nat Acad Sci USA 72:1004–1006, 1975
Coffins SJ, Ruscetti FW, Gallagher RE, Gallo RC: Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc Nat Acad Sci USA 75:2458–2462, 1978
Rice LM, Wheeler JW, Geschickter CF: Spirans XXII. Synthesis of 4,4-Dialkyl-4-Germacyclohexane and 8,8-Dialkyl-8-Germa-Azaspiro (4,5) Decanes. J Heterocyclic Chem 11:1041–1046, 1974
Oken MN, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (CCT) 5:649–655, 1982
Author information
Authors and Affiliations
Additional information
Other participating institutions include: Case Western Reserve University, Cleveland, OH (CA 14548); Chicago Medical School, Chicago, IL (CA 14144); Fox Chase Cancer Center, Philadelpha, PA (CA 18281); Hawaii Medical Association, Honolulu, HI; Mayo Clinic, Rochester, MN (CA 13650); Medical College of Ohio, Toledo, OH; New York University Medical Center, New York, NY (CA 16395); Northwestern University Medical Center, Chicago, IL (CA 17145); Hospital of the University of Pennsylvania, Philadelphia, PA (CA 15488); University of Pittsburgh, Pittsburgh, PA (CA 18653); Roswell Park Memorial Institute, Buffalo, NY (CA 12296); Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL (CA 25988); Natalie Warren Bryant Cancer Center, Tulsa, OK; Vermont Regional Cancer Center, Burlington, VT; University of Wisconsin Clinical Cancer Center, Madison, WI (CA 21076).
Dr. Ettinger is an American Cancer Society, Maryland Division, Professor of Clinical Oncology.
Rights and permissions
About this article
Cite this article
Ettinger, D.S., Finkelstein, D.M., Abeloff, M.D. et al. Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer. Invest New Drugs 8, 183–185 (1990). https://doi.org/10.1007/BF00177255
Issue Date:
DOI: https://doi.org/10.1007/BF00177255